Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference

Rhea-AI Summary

Kalaris Therapeutics (NASDAQ: KLRS), a clinical-stage biopharmaceutical company focused on retinal disease treatments, announced its participation in the Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference. The company's management team, including CEO Andrew Oxtoby and CMO Matthew Feinsod, will deliver a presentation in a fireside Q&A format on Thursday, June 5th, 2025, at 3:00 PM ET. The presentation will be accessible via webcast, with a replay available afterward on Kalaris' Investor Relations webpage. The company aims to showcase its developments in retinal disease therapeutics to the investment community.

PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference. The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience. 

Details:

• Type: Company Presentation
• Speakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical Officer
• Date: Thursday, June 5^th, 2025
• Time: 03:00 pm ET
• Location: Webcast
  

Following the event, a replay will be hosted on Kalaris Therapeutics’ Investor Relations webpage.

About Kalaris

Kalaris is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. The company is focused on development of TH103, a novel, differentiated anti-VEGF investigational therapy. Developed by Dr. Napoleone Ferrara, TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is currently being evaluated in an ongoing, Phase 1 clinical trial for the treatment of neovascular Age-related Macular Degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO).

Kalaris Therapeutics Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
+1 212 915 2577
cdavis@lifesciadvisors.com
ir@kalaristx.com

FAQ

When is Kalaris Therapeutics (KLRS) presenting at the Noble Capital Markets Conference?

Kalaris Therapeutics will present on Thursday, June 5th, 2025, at 3:00 PM ET during the Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference.

Who will be presenting for Kalaris Therapeutics (KLRS) at the Noble Conference?

Andrew Oxtoby, Chief Executive Officer, and Matthew Feinsod, Chief Medical Officer, will be presenting for Kalaris Therapeutics.

What type of diseases does Kalaris Therapeutics (KLRS) focus on?

Kalaris Therapeutics is focused on developing and commercializing treatments for prevalent retinal diseases.

Where can investors watch the replay of Kalaris Therapeutics' (KLRS) presentation?

A replay of the presentation will be available on Kalaris Therapeutics' Investor Relations webpage following the event.